Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance
20 April 2016
Pharma and Biotech organizations are facing growing challenges from the rapidly developing pharmacovigilance landscape and demands for the collection of more relevant safety data. These factors, combined with the pressure of cost containment, demand that life science organisations consider different approaches to the traditional, largely manual PV processes.
A risk-based processing approach introduces a highly effective and efficient process to manage drug safety, ensuring quality data is collected across the portfolio, from newly launched to established products.